Domača stranMOR • ETR
add
MorphoSys AG
Prejšnji trg. dan.
67,65 €
Dnevni razpon
67,65 € - 68,00 €
Letni razpon
14,52 € - 69,75 €
Tržna kapitalizacija
2,55 mrd. EUR
Povprečni obseg
66,52 tis.
Razm. P/E
-
Dividendna donosnost
-
Primarna borza
ETR
V novicah
Finančni podatki
Izkaz poslovnega izida
Prihodek
Čisti dohodek
| (EUR) | mar. 2024info | Sprememba L/L |
|---|---|---|
Prihodek | 27,54 mio. | 13,11 % |
Stroški poslovanja | 289,14 mio. | 264,02 % |
Čisti dohodek | −314,96 mio. | −608,87 % |
Čista dobičkovnost prihodkov | −1,14 tis. | −526,67 % |
Earnings per share | −8,27 | −529,19 % |
EBITDA | −263,38 mio. | −388,32 % |
Efektivna davčna stopnja | 0,51 % | — |
Bilanca stanja
Skupna sredstva
Skupne obveznosti
| (EUR) | mar. 2024info | Sprememba L/L |
|---|---|---|
Denar. in kratkor. naložbe | 630,77 mio. | −20,30 % |
Skupna sredstva | 1,83 mrd. | −17,85 % |
Skupne obveznosti | 2,09 mrd. | −1,84 % |
Celoten lastniški kapital | −261,67 mio. | — |
Shares outstanding | 37,62 mio. | — |
Razmerje P/B | −9,72 | — |
Donosnost sredstev | −34,27 % | — |
Donosnost kapitala | −41,11 % | — |
Denarni tok
Neto sprememba denarnih sredstev
| (EUR) | mar. 2024info | Sprememba L/L |
|---|---|---|
Čisti dohodek | −314,96 mio. | −608,87 % |
Denar iz dejavnosti | −71,53 mio. | 14,27 % |
Denar iz naložb | 28,62 mio. | 187,62 % |
Denar iz financiranja | −950,28 tis. | 97,86 % |
Neto sprememba denarnih sredstev | −27,24 mio. | 75,37 % |
Prost denarni tok | 246,91 mio. | 1.523,66 % |
Vizitka
MorphoSys AG is a German biopharmaceutical company founded in 1992. The company is headquartered near Munich, Germany, and has a wholly owned subsidiary, MorphoSys US Inc., in Boston, Massachusetts, in the US. The company has various antibody, protein and peptide technologies that it uses to discover and develop both proprietary and partnered drug candidates. The company has more than 100 drugs in its wider pipeline that are being investigated for a variety of diseases. While many of these are being developed in partnership with pharma and biotech companies, MorphoSys also has a proprietary pipeline with a focus on cancer and autoimmune diseases.
MorphoSys AG is listed on the Frankfurt Stock Exchange and on the US Nasdaq stock exchange. Novartis agreed to acquire the company in February 2024. Wikipedia
Generalni direktor
Datum ustanovitve
1992
Sedež organizacije
Spletno mesto
Zaposleni
464
